Grifols S.A. (GRFS) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Grifols S.A. (GRFS) over the past year, gaining 109.6% versus a loss of 21.8%. Over five years, TVTX leads with a +118.1% price change compared with -47.3% for GRFS. Grifols S.A. is the larger company by market cap ($5.04 billion vs $4.91 billion), about 1.0 times the size.
On valuation, Grifols S.A. trades at a lower forward P/E (5.1x vs 9.2x for Travere Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRFS | TVTX |
|---|---|---|
| Share price | $7.41 | $52.04 |
| Market cap | $5.04B | $4.91B |
| 1-day change | -1.20% | -2.62% |
| YTD return | -19.79% | +39.86% |
| 1-year return | -21.79% | +109.57% |
| 5-year return | -47.26% | +118.12% |
| P/E ratio (TTM) | 9.62 | — |
| Forward P/E | 5.14 | 9.23 |
| EPS (TTM) | $0.77 | $-0.74 |
| Dividend yield | 1.41% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $490.73M |
| Revenue growth (YoY) | — | +110.45% |
| Net income (latest FY) | — | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | — | -12.80% |
| Net margin | — | -5.21% |
| 52-week high | $9.90 | $68.73 |
| 52-week low | $6.96 | $22.59 |
| Distance from 52-week high | -25.15% | -24.28% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.69% | +44.52% |
| Average volume | 580.72K | 1.58M |
| Shares outstanding | 258.22M | 94.26M |
| Employees | 25,258 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TVTX has outperformed GRFS by 131.4 percentage points over the past year.
- Grifols S.A. offers a meaningfully higher dividend yield (1.41% vs 0.00%).
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
GRFS vs TVTX FAQ
Which is bigger, Grifols S.A. or Travere Therapeutics?
Grifols S.A. (GRFS) is larger, with a market capitalization of $5.04B compared with $4.91B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, GRFS or TVTX?
TVTX returned +109.57% over the past 12 months, compared with -21.79% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Grifols S.A. or Travere Therapeutics?
Grifols S.A. pays a dividend yielding 1.41%, while Travere Therapeutics does not currently pay a regular dividend.
Are Grifols S.A. and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.